Levofloxacin Hydrochloride Injection

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about 2 times that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. This product has the characteristics of a broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, and some Escherichia coli. It also has good antibacterial effects on some Staphylococci, Streptococcus pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Chlamydia, etc.

The main ingredient of this product is levofloxacin hydrochloride.

This product is a yellow-green clear liquid.

This product is suitable for the following moderate and severe infections caused by sensitive bacteria: respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis and infection, pneumonia, tonsillitis (peritonsillar abscess); urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); skin and soft tissue infections: infectious impetigo, cellulitis, lymphangiitis (adenitis), subcutaneous abscess, perianal abscess, etc.; intestinal infections: bacillary dysentery, infectious enteritis, salmonella enteritis, typhoid and paratyphoid; sepsis, neutropenia and various infections in immunocompromised patients; other infections: mastitis, trauma, burns and postoperative wound infection, abdominal cavity infection (metronidazole can be used in combination when necessary), cholecystitis, cholangitis, bone and joint infection and ENT infection, etc.

Intravenous drip: For adults, take 0.1-0.2g (1-2 vials) each time, add to 250ml 5% glucose injection, drip in about two hours, twice a day, or as directed by the doctor.

During medication, symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, abdominal distension, insomnia, dizziness, headache and other neurological symptoms and rash and itching may occur. Transient liver function abnormalities may also occur, such as increased blood transaminase and increased serum total bilirubin. The incidence of the above adverse reactions is between 0.1 and 5%. Occasionally, increased blood urea nitrogen, fatigue, fever, palpitations, abnormal taste, etc. are seen. Generally, they are well tolerated and disappear quickly after the end of the course of treatment.

It is contraindicated for patients who are allergic to quinolones.

Precautions for children: Not for use in patients under 18 years of age. Precautions for pregnancy and lactation: Not for use in pregnant or lactating women.

When this product is used simultaneously with magnesium or aluminum-containing antacids, sucralfate, metal cations (such as iron), zinc-containing multivitamin preparations and other drugs, it will interfere with the absorption of this product by the gastrointestinal tract, causing the concentration of this drug in various systems to be significantly reduced. Therefore, the time of taking the above drugs should be at least 2 hours before or after using this product. Avoid using it simultaneously with theophylline. If it is necessary to use it simultaneously, the blood concentration of theophylline should be monitored and the dosage should be adjusted accordingly. When used simultaneously with warfarin or its derivatives, the prothrombin time or other coagulation tests should be monitored. When used simultaneously with non-steroidal anti-inflammatory drugs, there is a possibility of causing convulsions. When used simultaneously with oral hypoglycemic drugs, it may cause blood sugar disorders, including hyperglycemia and hypoglycemia. Therefore, attention should be paid to monitoring blood sugar concentration during medication. Once hypoglycemia occurs, this product should be discontinued immediately and appropriate treatment should be given.

Keep in a light-proof and airtight container.

10ml:0.3g (based on C18H20FN3O4)

Yangzhou Zhongbao Pharmaceutical Co., Ltd.

• Founded in:

  1991-11-15

• Address:

  No. 91, Baoying Avenue, New District, Economic Development Zone, Baoying County, Yangzhou City, Jiangsu Province

• Tax NO.:

  91321000608709261R

• Registered Funds:

  60 million yuan

• Website:

  Log in to view

• Email:

  Log in to view